Project CASK has been named a collaborator in the Critical Path Institute TRxA 2026 BRIDGe program, an FDA-partnered drug development initiative. A CASK gene disorder submission has been accepted into the program, marking a meaningful step toward clinical translation for CASK-related disorders.